143 related articles for article (PubMed ID: 21968665)
1. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis Activity Measurement Standard.
Nestor MS; Ablon GR
J Drugs Dermatol; 2011 Oct; 10(10):1148-57. PubMed ID: 21968665
[TBL] [Abstract][Full Text] [Related]
2. The Frontalis Activity Measurement Standard: a novel contralateral method for assessing botulinum neurotoxin type-A activity.
Nestor MS; Ablon GR
J Drugs Dermatol; 2011 Sep; 10(9):968-72. PubMed ID: 22052264
[TBL] [Abstract][Full Text] [Related]
3. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.
Hexsel D; Brum C; do Prado DZ; Soirefmann M; Rotta FT; Dal'Forno T; Rodrigues TC
J Am Acad Dermatol; 2012 Aug; 67(2):226-32. PubMed ID: 22041253
[TBL] [Abstract][Full Text] [Related]
4. Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model.
Nestor MS; Ablon GR
J Clin Aesthet Dermatol; 2011 Sep; 4(9):43-9. PubMed ID: 21938269
[TBL] [Abstract][Full Text] [Related]
5. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
Allen SB; Goldenberg NA
Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727
[TBL] [Abstract][Full Text] [Related]
6. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS
Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059
[TBL] [Abstract][Full Text] [Related]
7. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
Schlessinger J; Monheit G; Kane MA; Mendelsohn N
Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
[TBL] [Abstract][Full Text] [Related]
8. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox.
Yang GC; Chiu RJ; Gillman GS
Arch Facial Plast Surg; 2008; 10(4):273-9. PubMed ID: 18645097
[TBL] [Abstract][Full Text] [Related]
9. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
Kim SB; Ban B; Jung KS; Yang GH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
[TBL] [Abstract][Full Text] [Related]
10. A two-center, open-label, randomized, split-face study to assess the efficacy and safety of one versus three intradermal injection sites of abobotulinumtoxinA in the treatment of lateral periocular rhytides.
Fabi SG; Sundaram H; Guiha I; Goldman MP
J Drugs Dermatol; 2013 Aug; 12(8):932-7. PubMed ID: 23986168
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles.
Michaels BM; Csank GA; Ryb GE; Eko FN; Rubin A
Aesthet Surg J; 2012 Jan; 32(1):96-102. PubMed ID: 22231417
[TBL] [Abstract][Full Text] [Related]
13. Fields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trial.
Hexsel D; Hexsel C; Siega C; Schilling-Souza J; Rotta FT; Rodrigues TC
JAMA Dermatol; 2013 Dec; 149(12):1386-91. PubMed ID: 24108521
[TBL] [Abstract][Full Text] [Related]
14. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
15. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
[TBL] [Abstract][Full Text] [Related]
16. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.
Nettar KD; Yu KC; Bapna S; Boscardin J; Maas CS
Arch Facial Plast Surg; 2011; 13(6):380-6. PubMed ID: 21690460
[TBL] [Abstract][Full Text] [Related]
17. RimabotulinumtoxinB vs. onabotulinumtoxinA for the treatment of forehead lines: an evaluator-blind, randomized, pilot study.
Lee DH; Kang SM; Feneran A; Youn CS; Kim JK; Cho S; Won CH; Chang SE; Lee MW; Choi JH; Moon KC
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e1-7. PubMed ID: 23030660
[TBL] [Abstract][Full Text] [Related]
18. Muscle atrophy beyond the clinical effect after a single dose of OnabotulinumtoxinA injected in the procerus muscle: a study with magnetic resonance imaging.
Koerte IK; Schroeder AS; Fietzek UM; Borggraefe I; Kerscher M; Berweck S; Reiser M; Ertl-Wagner B; Heinen F
Dermatol Surg; 2013 May; 39(5):761-5. PubMed ID: 23379599
[TBL] [Abstract][Full Text] [Related]
19. Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids.
Kassir R; Kolluru A; Kassir M
Dermatol Ther (Heidelb); 2013 Dec; 3(2):179-89. PubMed ID: 24318416
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
